3-{4-[(ethoxycarbonyl)oxy]-3,5-dimethoxybenzoyl}-2,6-dimethoxyphenyl chloroacetate | 1344112-12-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-{4-[(ethoxycarbonyl)oxy]-3,5-dimethoxybenzoyl}-2,6-dimethoxyphenyl chloroacetate
• 英文别名: [3-(4-Ethoxycarbonyloxy-3,5-dimethoxybenzoyl)-2,6-dimethoxyphenyl] 2-chloroacetate；[3-(4-ethoxycarbonyloxy-3,5-dimethoxybenzoyl)-2,6-dimethoxyphenyl] 2-chloroacetate
• CAS: 1344112-12-4
• 化学式: C₂₂H₂₃ClO₁₀
• 分子量: 482.872
• InChiKey: SGUJPJVHVVWMQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.63
• 重原子数：
  33.0
• 可旋转键数：
  10.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  115.82
• 氢给体数：
  0.0
• 氢受体数：
  10.0

反应信息

• 作为反应物：
  描述：

  3-{4-[(ethoxycarbonyl)oxy]-3,5-dimethoxybenzoyl}-2,6-dimethoxyphenyl chloroacetate 在 水 、 sodium acetate 、 C.I.酸性橙108 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 6.0h， 生成 (3-hydroxy-2,4-dimethoxyphenyl)(4-hydroxy-3,5-dimethoxyphenyl)methanone
  参考文献：
  名称：

  吩他汀代谢产物的合成及生物学评价

  摘要：

  以前对非那他汀与大鼠和人类微粒体组分温育的研究表明形成了九种主要代谢产物。现在已经通过合成确认了其中8种代谢物的结构，并报道了它们的生物学特性。伊顿的试剂被用作便利的缩合剂，除其他外，还可以简单地制得数克规模的芬他汀。评价了合成代谢产物和相关化合物在NCI-60癌细胞系中的抗增殖活性，以及​​它们对微管组装的影响。代谢物23（2'-甲氧吩他汀）表现出最有效的体外细胞毒性活性：抑制K-562，NCI-H322M，NCI-H522，KM12，M14，MDA-MB-435，NCI / ADR-RES，和带有GI的HS 578T细胞系50个值<10 nM。它也显示出比亲本芬他汀（3）更显着的微管蛋白聚合抑制活性（IC 50  = 3.2μM对15.0μM ），并在鼠白血病DA1-3b细胞中诱导G2 / M阻滞。对这种活性代谢产物的鉴定导致了具有强大的体外细胞毒性和抑制微管组装的类似物的设计和合成。

  DOI：

  10.1016/j.bmc.2011.08.047
• 作为产物：
  描述：

  2,6-二甲氧基苯酚 在 甲烷磺酸 、 四磷十氧化物 作用下， 反应 10.0h， 生成 3-{4-[(ethoxycarbonyl)oxy]-3,5-dimethoxybenzoyl}-2,6-dimethoxyphenyl chloroacetate
  参考文献：
  名称：

  吩他汀代谢产物的合成及生物学评价

  摘要：

  以前对非那他汀与大鼠和人类微粒体组分温育的研究表明形成了九种主要代谢产物。现在已经通过合成确认了其中8种代谢物的结构，并报道了它们的生物学特性。伊顿的试剂被用作便利的缩合剂，除其他外，还可以简单地制得数克规模的芬他汀。评价了合成代谢产物和相关化合物在NCI-60癌细胞系中的抗增殖活性，以及​​它们对微管组装的影响。代谢物23（2'-甲氧吩他汀）表现出最有效的体外细胞毒性活性：抑制K-562，NCI-H322M，NCI-H522，KM12，M14，MDA-MB-435，NCI / ADR-RES，和带有GI的HS 578T细胞系50个值<10 nM。它也显示出比亲本芬他汀（3）更显着的微管蛋白聚合抑制活性（IC 50  = 3.2μM对15.0μM ），并在鼠白血病DA1-3b细胞中诱导G2 / M阻滞。对这种活性代谢产物的鉴定导致了具有强大的体外细胞毒性和抑制微管组装的类似物的设计和合成。

  DOI：

  10.1016/j.bmc.2011.08.047

文献信息

• Enhanced antitumor potential induced by chloroacetate-loaded benzophenones acting as fused tubulin-pyruvate dehydrogenase kinase 1 (PDHK1) ligands
  作者：Alina Ghinet、Xavier Thuru、Emilie Floquet、Joëlle Dubois、Amaury Farce、Benoît Rigo

  DOI：10.1016/j.bioorg.2020.103643

  日期：2020.3

  The majority of cancers detected every year are treated with anti-cancer compounds. Unfortunately, many tumors become resistant to antineoplastic drugs. One option is to use cocktails of compounds acting on different targets to try to overcome the resistant cells. This type of approach can produce good results, but is often accompanied by a sharp increase of associated side effects.The strategy presented herein focuses on the use of a single compound acting on two different biological targets enhancing potency and lowering the toxicity of the chemotherapy. In this light, the approach presented in the current study involves the dual inhibition of human pyruvate dehydrogenase kinase-1 (PDHK1) and tubulin polymerization using mono-, di- and tri-chloroacetate-loaded benzophenones and benzothiophenones.Synthesized molecules were evaluated in vitro on tubulin polymerization and on pyruvate dehydrogenase kinase 1. The cell cycle distribution after treatment of DA1-3b leukemic cells with active compounds was tested.Twenty-two benzo(thio)phenones have been selected by the National Cancer Institute (USA) for evaluation of their anti-proliferative potential against NCI-60 cancer cell lines including multidrug-resistant tumor cell lines. Seventeen molecules proved to be very effective in combating the growth of tumor cells exhibiting inhibitory activities up to nanomolar range.The molecular docking of best antitumor molecules in the study was realized with GOLD in the tubulin and PDHK1 binding sites, and allowed to understand the positioning of active molecules.Chloroacetate-loaded benzo(thio)phenones are dual targeted tubulin- and pyruvate dehydrogenase kinase 1 (PDHK1)-binding antitumor agents and exhibited superior antitumor activity compared to non-chlorinated congeners particularly on leukemia, colon, melanoma and breast cancer cell lines.
• Synthesis and biological evaluation of phenstatin metabolites
  作者：Alina Ghinet、Benoît Rigo、Jean-Pierre Hénichart、Delphine Le Broc-Ryckewaert、Jean Pommery、Nicole Pommery、Xavier Thuru、Bruno Quesnel、Philippe Gautret

  DOI：10.1016/j.bmc.2011.08.047

  日期：2011.10

  metabolites. The structures of eight of these metabolites have been now confirmed by synthesis and their biological properties have been reported. Eaton’s reagent was utilized as a convenient condensing agent, allowing, among others, a simple multigram scale preparation of phenstatin. Synthesized metabolites and related compounds were evaluated for their antiproliferative activity in the NCI-60 cancer cell

  以前对非那他汀与大鼠和人类微粒体组分温育的研究表明形成了九种主要代谢产物。现在已经通过合成确认了其中8种代谢物的结构，并报道了它们的生物学特性。伊顿的试剂被用作便利的缩合剂，除其他外，还可以简单地制得数克规模的芬他汀。评价了合成代谢产物和相关化合物在NCI-60癌细胞系中的抗增殖活性，以及​​它们对微管组装的影响。代谢物23（2'-甲氧吩他汀）表现出最有效的体外细胞毒性活性：抑制K-562，NCI-H322M，NCI-H522，KM12，M14，MDA-MB-435，NCI / ADR-RES，和带有GI的HS 578T细胞系50个值<10 nM。它也显示出比亲本芬他汀（3）更显着的微管蛋白聚合抑制活性（IC 50  = 3.2μM对15.0μM ），并在鼠白血病DA1-3b细胞中诱导G2 / M阻滞。对这种活性代谢产物的鉴定导致了具有强大的体外细胞毒性和抑制微管组装的类似物的设计和合成。